Analyst Reco. FibroGen, Inc.

Equities

FGEN

US31572Q8087

Real-time Estimate Cboe BZX Other stock markets 11:05:18 2024-05-10 am EDT			5-day change	1st Jan Change
1.185 ^USD	-2.87%		+2.19%	+31.45%

May. 07	Top Premarket Gainers	MT
May. 06	Transcript : FibroGen, Inc., Q1 2024 Earnings Call, May 06, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Analyst recommendations: Hewlett Packard, Apple, Tesla, Mosaic, Rite Aid...	23-08-30
BofA Downgrades FibroGen to Underperform From Neutral, Adjusts Price Target to $2 From $4	23-08-08	MT
BofA Securities Downgrades FibroGen to Neutral From Buy, Lowers Price Target to $4 From $29 After Drug Fails to Meet Phase 3 Trial Goal	23-06-27	MT
BofA Securities Downgrades FibroGen to Neutral From Buy, Lowers Price Target to $4 From $29	23-06-27	MT
Goldman Sachs Adjusts FibroGen's Price Target to $2 From $16, Keeps Sell Rating	23-06-27	MT
Stifel Downgrades FibroGen to Hold From Buy, Cuts Price Target to $11 From $28	23-06-26	MT
William Blair Downgrades FibroGen to Market Perform From Outperform	23-06-26	MT
Raymond James Downgrades FibroGen to Market Perform From Outperform	23-06-26	MT
Stifel Upgrades FibroGen to Buy From Hold	23-06-02	MT
Cowen Adjusts Price Target on FibroGen to $25 From $15, Maintains Market Perform Rating	23-02-28	MT
Goldman Sachs Increases Price Target on FibroGen to $16 From $9, Maintains Sell Rating	23-02-21	MT
William Blair Upgrades FibroGen to Outperform From Market Perform	23-01-31	MT
Raymond James Upgrades FibroGen to Outperform From Market Perform, Price Target is $35	23-01-26	MT
BofA Securities Upgrades FibroGen to Buy From Neutral, Adjusts Price Target to $27 From $18	23-01-05	MT
Goldman Sachs Adjusts Price Target on FibroGen to $9 From $8, Maintains Sell Rating	22-11-08	MT
Goldman Sachs Adjusts FibroGen's Price Target to $8 from $9, Keeps Sell Rating	22-05-24	MT
Goldman Sachs Trims Price Target for FibroGen to $9 From $10, Maintains Sell Rating	22-03-01	MT
FIBROGEN : Goldman Sachs Downgrades FibroGen to Sell Rating From Neutral, Adjusts Price Target to $11 From $16	21-09-22	MT
FIBROGEN : Raymond James Upgrades FibroGen to Market Perform From Underperform	21-08-20	MT
FIBROGEN : Goldman Sachs Further Cuts FibroGen's Price Target to $16 From $22, Maintains Neutral Rating	21-08-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. FibroGen, Inc.

Equities

FGEN

US31572Q8087

Analyst Reco.

Filters